## Supplementary Table 1. Demographic, clinical and pathological characteristics of the study cohort.

	N	PMI <sup>1</sup> (h)	Sex (M/F)	Age (y)	Duration <sup>2</sup> (y)	Braak Stage <sup>3</sup>
Control	7	15.4 ± 6.4	3/4	71.6 ± 5.8	n/a	0
MSA	11	13.1 ± 5.9	5/6	68.1 ± 10.7	$7.4 \pm 3.6$	0 - IV

postmortem interval;
disease duration from first clinical diagnosis until death;
Braak staging for Parkinson's pathology